NEW YORK (GenomeWeb) — PrediLife said today that it has signed on the Institut Curie to perform the genetic analysis portion of its MammoRisk breast cancer risk assay.
MammoRisk — used in conjunction with mammograms — is designed to determine breast cancer risk using a patient's age, breast density, family history, and breast biopsy history, as well as a polygenic score based on the analysis of disease-linked genetic variations from a saliva sample.